Drug Trial Radar · NCT06660719
Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care
Last checked: Nov 20, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
852
Planned (sponsor's estimate)
Start
Feb 14, 2025
Primary completion
Mar 30, 2027
Study completion Mar 30, 2027
Sponsor
- Lead sponsor
- Shin Poong Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study is designed to evaluate the efficacy and safety of the combination therapy of SP-8203 (otaplimastat) and thrombolytic standard of care in acute ischemic stroke patient. As a standard of care, thrombolytic therapy (for instance, recombinant tissue plasminogen activator) will be administered. When reperfusion is not achieved in spite of thrombolytic therapy, endovascular therapy can be performed.
Conditions
- Ischemic Stroke
Interventions
SP-8203Drug
SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
PlaceboDrug
Placebo will be intravenously administered twice daily (intervals of 12 hours)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with modified Rankin Scale (mRS) 0-1Time frame: Day 90
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Dong-A University Hospital
Busan, South Korea · Recruiting
Ulsan University Hospital
Ulsan, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.